Abattis Bioceuticals Corp ATTBF

Also what’s new with Abattis

[fasttrack5]

What's New with Abattis

Acquisitions 

In addition to the recent acquisition of Pro Natura BV, the Company has also signed an agreement to purchase NutriVida.  This acquisition continues to await CSE approval.
 
Operations

The Company continues to remain focused on driving revenue growth through strategic acquisitions and the organic growth of its various divisions. This includes:

• Incorporating Pro Natura into the Company’s vertically integrated operations
• In addition to the >100 products Pro Natura sells, the Company hopes to commence shipping COMFORT to the Netherlands to extend sales into the European Market;
• Vergence continues its research, development and sales efforts;
• Green Tree continues to sell its Abattis branded vape pens to wholesale buyers across Canada;
• Gabriola continues to advance its LP application for a Cultivation and Sales License;
• Abattis is continuing its research and development efforts focused on the nano-emulsification of cannabinoids with UBC and MITACS. 

Management & Administrative Changes

In light of the recent cease trade and delay in filing its financial statements, the Company has made significant changes to its personnel and Board of Directors. Jim Irving and Wolfgang Richter have stepped down as Directors of the Company, and Kent McParland has been replaced by Francesco Paolini as CFO and Director. The Company thanks each of these individuals for their tenure at Abattis and wishes them all the best.
 
With the recent changes to our management and Board of Directors, we are hopeful we will be able to complete our audit and file the required annual filings in order to lift the current cease trade order on the Company and resume trading as soon as possible. The Company will keep our stakeholders apprised of any material developments with respect to this matter as they occur.


Frequently Asked Questions

Below you will find the answers to some commonly asked questions we receive via our various communication channels.

What is a CTO?
A Cease Trade Order (CTO), is an order that prohibits all trading in securities of a particular company for a period of time.

Why are you under a CTO?
The Company is under CTO due to its delay in filing its audited financial statements for the fiscal year ended September 30, 2018.

Are you still trading on the TSX?
Abattis has only traded on the CSE and the OTC.

Why is Abattis trading on the OTC, but not the CSE?
The CTO was implemented by the British Columbia Securities Commission (BCSC) and the Canadian Stock Exchange (CSE).  The OTC is not regulated by these two bodies and therefore the shares continue to trade on the OTC’s pink market. Please note that the OTC pink market provides limited regulatory oversight and is designed for investors with a high risk-tolerance for trading companies with limited information available. We advise our investors to proceed with caution before executing trades in our stock through the OTC pink market.

How do I sell or buy shares? 
Whilst the Company remains subject to the current CTO, no shares can be bought or sold on the CSE. However, these functions still remain available on the OTC pink market under the trading symbol ATTBF. 

See “Why is Abattis trading on the OTC, but not the CSE?” above.

When will the shares be trading again?
In order to satisfy the requirements of the CSE and BCSC, we are required to file our audited financial statements for the fiscal year ended September 30, 2018 and the related Management Discussion and Analysis (the “Annual Filings”).

We are working diligently with our auditors and it is our full intention to reinstate trading as soon as possible.  We remain confident that this will happen once we submit our Annual Filings. 

Is the Company still operational?
Despite the current cease trade, the Company is busier than ever before.  As reflected in the “What’s New” section above, the Company continues to build value across all its divisions and has started earning revenues through sales in both Vergence and Pro Natura.
-
Please stay tuned for additional updates in the near future. If you have any comments or inquiries, please direct them to our Investor Relations at [e-mail] or give us a call at [phone].